Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Non-Current Assets: 2019-2024

Historic Non-Current Assets for Allogene Therapeutics (ALLO) over the last 6 years, with Dec 2024 value amounting to $245.3 million.

  • Allogene Therapeutics' Non-Current Assets fell 37.11% to $179.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $179.1 million, marking a year-over-year decrease of 37.11%. This contributed to the annual value of $245.3 million for FY2024, which is 33.53% up from last year.
  • As of FY2024, Allogene Therapeutics' Non-Current Assets stood at $245.3 million, which was up 33.53% from $183.7 million recorded in FY2023.
  • In the past 5 years, Allogene Therapeutics' Non-Current Assets ranged from a high of $579.5 million in FY2021 and a low of $183.7 million during FY2023.
  • Moreover, its 3-year median value for Non-Current Assets was $245.3 million (2024), whereas its average is $240.6 million.
  • In the last 5 years, Allogene Therapeutics' Non-Current Assets surged by 120.92% in 2020 and then crashed by 49.48% in 2022.
  • Yearly analysis of 5 years shows Allogene Therapeutics' Non-Current Assets stood at $382.7 million in 2020, then spiked by 51.43% to $579.5 million in 2021, then tumbled by 49.48% to $292.8 million in 2022, then plummeted by 37.24% to $183.7 million in 2023, then soared by 33.53% to $245.3 million in 2024.